Soufflé Therapeutics Raises $135M for Tissue-Specific RNA Medicines

What happened

Soufflé Therapeutics has raised an oversubscribed $135 million Series B led by Juvia. The financing will support development of RNA medicines designed to act selectively in targeted tissues.

Why it matters

RNA-based therapies can address disease biology that is difficult to reach with conventional drugs, but delivery remains a central challenge. Tissue-specific approaches aim to concentrate therapeutic activity where it is needed while limiting exposure elsewhere in the body.

The bigger picture

The round illustrates continued investor interest in platform biotechnologies that pair novel drug design with improved delivery. The company's value will ultimately depend on translating that platform promise into convincing preclinical and clinical evidence.